	US 12,187,767 B2
	Compositions and methods for treating SARS-CoV-2 infections
Vincent C. Bond, Stone Mountain, GA (US); Ming Bo Huang, Atlanta, GA (US); and James W. Lillard, Jr., Smyrna, GA (US)
Assigned to MOREHOUSE SCHOOL OF MEDICINE, Atlanta, GA (US)
Filed by MOREHOUSE SCHOOL OF MEDICINE, Atlanta, GA (US)
Filed on Jun. 9, 2022, as Appl. No. 17/806,210.
Application 17/380,786 is a division of application No. 17/339,197, filed on Jun. 4, 2021, granted, now 11,180,534, issued on Nov. 23, 2021.
Application 17/806,210 is a continuation of application No. 17/380,786, filed on Jul. 20, 2021, granted, now 11,414,462.
Prior Publication US 2022/0389063 A1, Dec. 8, 2022
Int. Cl. C07K 14/16 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01); A61K 47/54 (2017.01); A61K 47/60 (2017.01); A61P 31/14 (2006.01)

CPC C07K 14/163 (2013.01) [A61K 45/06 (2013.01); A61K 47/542 (2017.08); A61K 47/60 (2017.08); A61P 31/14 (2018.01); A61K 38/00 (2013.01)]

16 Claims

1. A method for treating a SARS-CoV-2 infection, comprising:

administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a virus-inhibiting secretion modifying region (VI-SMR) peptide comprising an SMR peptide from HIV-1 Nef in combination with a cell penetrating peptide (CPP).